Skip to content

Sustainable Plant Protection Transition: a Global Health Approach (SPRINT)

Sustainable Plant Protection Transition: a Global Health Approach (SPRINT) - SPRINT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50994
Enrollment
72
Registered
2021-03-01
Start date
2021-03-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Niet van toepassing Not applicable

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18 y or higher age on the day of recruitment Males and females

Exclusion criteria

Exclusion criteria: Individuals are not able to speak and/or read Dutch will be excluded

Design outcomes

Primary

MeasureTime frame
The following biomarkers will be studied in all study participants: 1. In blood: a. blood cell counts b. general inflammatory/immunologic status: hsCRP, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13 and TNF-a c. ROS-biomarkers: GSH/GSSG 2. In urine: PPP components and their metabolites, urinary electrolytes, creatinine, and urinary proteins (OBS) 3. In stool: microbiome analysis 4. In nasal swaps: microbiome analysis

Secondary

MeasureTime frame
Secondary study outcomes in blood: a. Sister chromatid exchanges (SCE), b. Reticulocyte and lymphocyte micronuclei (MN), c. Comets d. Other inflammatory markers: SAA, VCAM-1 and ICAM-1 e. Neurotoxicity biomarkers: AChE, BChE, GFAP f. Kidney function: creatinine, g. Thyroid: fT4, T3, TSH h. Liver function: ALT, AST, GGT and protein electrophoresis i. Reproductive: DHEAS, FSH, GGT, LH, s-DHEA, SHBG, testosterone, estradiol, progesterone and cortisol j. Untargeted exposome analysis (exogenous) k. Untargeted metabolome analysis (endogenous) Secondary study outcomes in urine a. KID1, NAG

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)